You are invited to participate in a research study of a human immune cell-line antibody upon language, memory, and symptoms of schizophrenia. This human immune cell-line antibody, canakinumab, is a class of medication that decreases the levels of the protein interleukin-1beta (IL-1β). The IL-1β protein is produced in response to inflammation in your body and canakinumab can decrease IL-1β protein and inflammation by blocking the pathway. We hope to learn how this human immune cell-line antibody in addition to your normal antipsychotic medication can also improve thought processing and reduce symptoms in people with schizophrenia and to determine if this human immune cell-line antibody can be used as a new therapeutic treatment for thinking problems and symptoms in people with schizophrenia.